News

Public · Published

Key facts: Amgen Raises Outlook; Drug Growth; MariTide Trials Advance

Amgen reported third-quarter revenue of $10.365 billion, up 8%, and adjusted earnings per share of $6.45, both above estimates. It raised its 2026 revenue outlook to $38.9–$39.7 billion and adjusted earnings-per-share outlook to $22.90–$23.70, while advancing Phase 3 MariTide trials.

Published:

Updated:

What happened

Amgen reported third-quarter revenue of $10.365 billion, up 8%, and adjusted earnings per share of $6.45, both above estimates. It raised its 2026 revenue outlook to $38.9–$39.7 billion and adjusted earnings-per-share outlook to $22.90–$23.70, while advancing Phase 3 MariTide trials.

Confirmed

Global impact / market context

Higher guidance signals management expects stronger sales and earnings than previously indicated, which can support investor expectations for future cash generation. Growth across several medicines may offset falling Prolia and XGEVA sales as biosimilar competition, meaning similar lower-cost drugs, pressures those products.

Analyst inference

The article reports mixed product trends: several medicines grew, but Prolia and XGEVA declined amid biosimilar competition. Analysts’ average 12-month price target was $410.82, implying 11% downside from the Nov. 3 close, while their overall rating remained Hold.

Confirmed

What to watch

  1. Watch whether coming quarterly results show revenue growth across the named medicines can offset continued Prolia and XGEVA declines from biosimilar competition. Analyst inference
  2. Amgen expects initial MariTide trial results next year; study findings and four-times-yearly dosing tests could clarify its potential role in obesity and related conditions. Confirmed
  3. Full OASIZ-301 results are due at an industry conference in November; the data may add detail on dazodalibep’s effect on Sjögren’s disease symptoms. Confirmed

Evidence

  • Original source link unavailable